Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

204

Enrollment

INDUSTRY

Sponsor class

Stopped Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.

Conditions

Obesity

Interventions

DRUG: Oral Azelaprag (BGE-105)
DRUG: Oral Placebo for Azelaprag (BGE-105)
DRUG: Tirzepatide
DRUG: Tirzepatide Placebo

Sponsor

BioAge Labs, Inc.

Collaborators

[object Object]